• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过CRISPR干扰筛选鉴定出非霍奇金淋巴瘤细胞存活所必需的免疫球蛋白重链增强子中的核心区域。

Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen.

作者信息

Kasprzyk Marta Elżbieta, Sura Weronika, Podralska Marta, Kazimierska Marta, Seitz Annika, Łosiewski Wojciech, Woźniak Tomasz, Guikema Jeroen E J, Diepstra Arjan, Kluiver Joost, Van den Berg Anke, Rozwadowska Natalia, Dzikiewicz-Krawczyk Agnieszka

机构信息

Institute of Human Genetics, Polish Academy of Sciences, Poznań.

Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen.

出版信息

Haematologica. 2024 Dec 1;109(12):4007-4020. doi: 10.3324/haematol.2023.284672.

DOI:10.3324/haematol.2023.284672
PMID:38934080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609794/
Abstract

Chromosomal translocations in non-Hodgkin lymphoma (NHL) result in activation of oncogenes by placing them under the regulation of immunoglobulin heavy chain (IGH) super-enhancers. Aberrant expression of translocated oncogenes induced by enhancer activity can contribute to lymphomagenesis. The role of the IGH enhancers in normal B-cell development is well established, but knowledge regarding the precise mechanisms of their involvement in control of the translocated oncogenes is limited. The goal of this project was to define the critical regions in the IGH regulatory elements and identify enhancer RNA (eRNA). We designed a single guide RNA library densely covering the IGH enhancers and performed tiling CRISPR interference screens in three NHL cell lines. This revealed three regions crucial for NHL cell growth. With chromatin- enriched RNA sequencing we showed transcription from the core enhancer regions and subsequently validated expression of the eRNA in a panel of NHL cell lines and tissue samples. Inhibition of the essential IGH enhancer regions decreased expression of eRNA and translocated oncogenes in several NHL cell lines. The observed expression and growth patterns were consistent with the breakpoints in the IGH locus. Moreover, targeting the Eμ enhancer resulted in loss of B-cell receptor expression. In a Burkitt lymphoma cell line, MYC overexpression partially rescued the phenotype induced by IGH enhancer inhibition. Our results indicated the most critical regions in the IGH enhancers and provided new insights into the current understanding of the role of IGH enhancers in B-cell NHL. As such, this study forms a basis for development of potential therapeutic approaches.

摘要

非霍奇金淋巴瘤(NHL)中的染色体易位通过将癌基因置于免疫球蛋白重链(IGH)超级增强子的调控之下,导致癌基因激活。增强子活性诱导的易位癌基因异常表达可促进淋巴瘤的发生。IGH增强子在正常B细胞发育中的作用已得到充分证实,但关于其参与调控易位癌基因的确切机制的了解有限。本项目的目标是确定IGH调控元件中的关键区域并鉴定增强子RNA(eRNA)。我们设计了一个密集覆盖IGH增强子的单向导RNA文库,并在三种NHL细胞系中进行了平铺式CRISPR干扰筛选。这揭示了对NHL细胞生长至关重要的三个区域。通过染色质富集RNA测序,我们显示了核心增强子区域的转录,并随后在一组NHL细胞系和组织样本中验证了eRNA的表达。抑制必需的IGH增强子区域可降低几种NHL细胞系中eRNA和易位癌基因的表达。观察到的表达和生长模式与IGH基因座中的断点一致。此外,靶向Eμ增强子导致B细胞受体表达丧失。在伯基特淋巴瘤细胞系中,MYC过表达部分挽救了IGH增强子抑制诱导的表型。我们的结果表明了IGH增强子中最关键的区域,并为目前对IGH增强子在B细胞NHL中的作用的理解提供了新的见解。因此,本研究为潜在治疗方法的开发奠定了基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/e876974c3f25/1094007.fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/205044d19609/1094007.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/247d694f05ce/1094007.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/0e6b3b0e966d/1094007.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/fde40d6bfbee/1094007.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/e876974c3f25/1094007.fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/205044d19609/1094007.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/247d694f05ce/1094007.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/0e6b3b0e966d/1094007.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/fde40d6bfbee/1094007.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a973/11609794/e876974c3f25/1094007.fig5.jpg

相似文献

1
Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen.通过CRISPR干扰筛选鉴定出非霍奇金淋巴瘤细胞存活所必需的免疫球蛋白重链增强子中的核心区域。
Haematologica. 2024 Dec 1;109(12):4007-4020. doi: 10.3324/haematol.2023.284672.
2
7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth - A question of specificity.7-[[(4-甲基-2-吡啶基)氨基](2-吡啶基)甲基]-8-喹啉醇(化合物30666)抑制增强子活性并减少B细胞淋巴瘤生长——特异性问题。
Eur J Pharmacol. 2021 Nov 5;910:174505. doi: 10.1016/j.ejphar.2021.174505. Epub 2021 Sep 14.
3
Discovery platform for inhibitors of IgH gene enhancer activity.IgH 基因增强子活性抑制剂的发现平台。
Cancer Biol Ther. 2019;20(4):571-581. doi: 10.1080/15384047.2018.1538615. Epub 2018 Nov 27.
4
Mouse Models of Deregulation Driven by IgH Locus Enhancers as Models of B-Cell Lymphomagenesis.IgH 基因座增强子驱动失调的小鼠模型作为 B 细胞淋巴瘤发生的模型。
Front Immunol. 2020 Jul 23;11:1564. doi: 10.3389/fimmu.2020.01564. eCollection 2020.
5
Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.免疫球蛋白重链基因3'增强子中的调控元件可诱导小鼠B细胞中的c-myc失调和淋巴瘤发生。
J Biol Chem. 2005 Apr 1;280(13):12766-73. doi: 10.1074/jbc.M412446200. Epub 2005 Feb 1.
6
In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.在免疫球蛋白重链(IGH)/MYC易位模型中,Igh 3'调控区在B细胞发育的未成熟阶段诱导MYC表达。
Genes Chromosomes Cancer. 2007 Oct;46(10):950-9. doi: 10.1002/gcc.20480.
7
NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.免疫球蛋白重链增强子对c-myc表达的失调需要NF-κB活性。
J Biol Chem. 2000 Oct 13;275(41):32338-46. doi: 10.1074/jbc.M004148200.
8
The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.免疫球蛋白重链基因3'增强子在t(14;18)淋巴瘤细胞中使bcl-2启动子的使用失调。
Oncogene. 2007 Apr 19;26(18):2635-41. doi: 10.1038/sj.onc.1210061. Epub 2006 Oct 16.
9
Enhancer RNA AL928768.3 from the IGH Locus Regulates MYC Expression and Controls the Proliferation and Chemoresistance of Burkitt Lymphoma Cells with IGH/MYC Translocation.IGH 基因座上的增强子 RNA AL928768.3 调控 MYC 表达,并控制IGH/MYC 易位的伯基特淋巴瘤细胞的增殖和化疗耐药性。
Int J Mol Sci. 2022 Apr 21;23(9):4624. doi: 10.3390/ijms23094624.
10
Functional long-range interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells.t(14;18)淋巴瘤细胞中IgH 3'增强子与bcl-2启动子区域的功能性长程相互作用。
Oncogene. 2008 Dec 4;27(53):6720-8. doi: 10.1038/onc.2008.286. Epub 2008 Aug 11.

引用本文的文献

1
Integrative genomic analysis identifies novel causal genes of Hodgkin's and non-Hodgkin's lymphoma.综合基因组分析确定了霍奇金淋巴瘤和非霍奇金淋巴瘤的新致病基因。
Discov Oncol. 2025 Jul 13;16(1):1324. doi: 10.1007/s12672-025-03101-1.
2
Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications.靶向肝癌中的超级增强子:从致病机制到临床应用
Front Pharmacol. 2025 Jun 18;16:1589455. doi: 10.3389/fphar.2025.1589455. eCollection 2025.

本文引用的文献

1
Enhancer RNA AL928768.3 from the IGH Locus Regulates MYC Expression and Controls the Proliferation and Chemoresistance of Burkitt Lymphoma Cells with IGH/MYC Translocation.IGH 基因座上的增强子 RNA AL928768.3 调控 MYC 表达,并控制IGH/MYC 易位的伯基特淋巴瘤细胞的增殖和化疗耐药性。
Int J Mol Sci. 2022 Apr 21;23(9):4624. doi: 10.3390/ijms23094624.
2
Enhancer RNA: What we know and what we can achieve.增强子 RNA:我们已知的和我们可以实现的。
Cell Prolif. 2022 Apr;55(4):e13202. doi: 10.1111/cpr.13202. Epub 2022 Feb 16.
3
7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth - A question of specificity.
7-[[(4-甲基-2-吡啶基)氨基](2-吡啶基)甲基]-8-喹啉醇(化合物30666)抑制增强子活性并减少B细胞淋巴瘤生长——特异性问题。
Eur J Pharmacol. 2021 Nov 5;910:174505. doi: 10.1016/j.ejphar.2021.174505. Epub 2021 Sep 14.
4
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.MYC:一种具有预后和治疗意义的多效癌基因,在血液恶性肿瘤中。
J Hematol Oncol. 2021 Aug 9;14(1):121. doi: 10.1186/s13045-021-01111-4.
5
Enhancing B-Cell Malignancies-On Repurposing Enhancer Activity towards Cancer.增强B细胞恶性肿瘤——关于将增强子活性重新用于癌症治疗
Cancers (Basel). 2021 Jun 29;13(13):3270. doi: 10.3390/cancers13133270.
6
The mechanism and function of super enhancer RNA.超级增强子 RNA 的作用机制和功能。
Genesis. 2021 Jun;59(5-6):e23422. doi: 10.1002/dvg.23422. Epub 2021 May 24.
7
Epidemiology of Non-Hodgkin's Lymphoma.非霍奇金淋巴瘤的流行病学。
Med Sci (Basel). 2021 Jan 30;9(1):5. doi: 10.3390/medsci9010005.
8
Mouse Models of Deregulation Driven by IgH Locus Enhancers as Models of B-Cell Lymphomagenesis.IgH 基因座增强子驱动失调的小鼠模型作为 B 细胞淋巴瘤发生的模型。
Front Immunol. 2020 Jul 23;11:1564. doi: 10.3389/fimmu.2020.01564. eCollection 2020.
9
Enhancer RNAs are an important regulatory layer of the epigenome.增强子 RNA 是表观基因组的一个重要调控层。
Nat Struct Mol Biol. 2020 Jun;27(6):521-528. doi: 10.1038/s41594-020-0446-0. Epub 2020 Jun 8.
10
BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas.B细胞非霍奇金淋巴瘤发病机制与治疗中的BCL-2蛋白
Cancers (Basel). 2020 Apr 10;12(4):938. doi: 10.3390/cancers12040938.